logo
Share SHARE
FONT-SIZE Plus   Neg

Repros Therapeutics To Meet With FDA To Discuss Phase 3 Study Design Of Androxal

Repros Therapeutics Inc.(RPRX: Quote) Monday said the FDA has scheduled a meeting in May to discuss the design of pivotal Phase 3 efficacy studies for Androxal, as well as the components of the overall drug development program required for NDA submission.

Androxal is an oral therapy intended for the treatment of secondary hypogonadism. Unlike the hormone replacement therapies currently approved to treat this disorder, Androxal restores testicular function resulting in normal synthesis of testosterone and continued spermatogenesis.

Repros said studies using approved testosterone replacement therapies as efficacy and safety comparators have shown the approved treatments result in suppression of important pituitary hormones that drive testicular function down to castration levels in a significant number of men.

Joseph Podolski, president and CEO of The Woodlands, Texas-based company, said," Our goal is to work with the FDA to provide a complete drug dossier for Androxal that exhibits the products' clinical benefit and safety. Depending on FDA comments, we believe we can submit the NDA early in 2014."

RPRX closed Monday's regular trade at $4.35, down $0.15 or 3.33%, on the Nasdaq. In the after-hours, the stock gained $0.01 or 0.23%. Over the past year, the stock traded in a range of $3.34 - $6.85.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Germanwings plane crash has spurred European airlines to implement stringent cockpit rules widely followed in the U.S., after it emerged a lone co-pilot forced the plane into its fatal descent, reports said on Thursday. Video-game retailer GameStop Corp. said Thursday after the markets closed that its fourth quarter profit rose 11% from last year, as better cost control helped offset a 5.6% decrease in sales. However, the company's quarterly earnings per share, excluding item, came in below analysts' expectations as did its quarterly sales. The Villages, a serene retirement hometown in Florida has been designated as the fastest-growing metro in the U.S. for the second consecutive year, as per Census estimates released on Thursday.
comments powered by Disqus
Follow RTT